Profile of Chemotherapeutic Treatment of Patients with Colorectal Cancer in a Hospital in Rio de Janeiro, Brazil
DOI:
https://doi.org/10.32635/2176-9745.RBC.2025v71n3.5223Keywords:
Colorectal Neoplasms/drug therapy, Drug Therapy, Drug Use, Survival AnalysisAbstract
Introduction: Colorectal cancer is one of the leading causes of cancer-related death. Differences can be observed in relation to chemotherapy treatment when comparing guidelines from the Brazilian Ministry of Health with those of scientific societies. In this context, real-world data studies may provide evidences regarding the necessity of adjustments of the currently used regimens. Objective: To identify the chemotherapy treatment profile of patients with colorectal cancer in an oncology hospital. Method: The study was conducted with data obtained from physical or electronic charts, histopathological test results, and chemotherapy prescriptions. The variables were grouped into three categories: sociodemographic, clinical, and treatment. Overall survival at 24 months was estimated using the Kaplan-Meier method. Results: The combined regimen of capecitabine and oxaliplatin was the most prescribed, being used for all therapeutic purposes. Neoadjuvant regimens associated with radiotherapy were exclusively for rectal cancer. The combination of fluorouracil and folinic acid was used as adjuvant therapy, and regimens containing irinotecan had palliative purpose. The overall survival at 24 months was 83.8% for neoadjuvant treatment, 86.8% for adjuvant treatment, and 44.3% for palliative treatment. Conclusion: The therapeutic regimens identified are aligned with those recommended by the guidelines of the Brazilian Ministry of Health. Most patients were diagnosed at advanced stages, which had a significant impact on survival. This highlights the necessity to access more effective therapies, further to actions focused to screening and monitoring current and future trends.
Downloads
References
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. doi: https://doi.org/10.3322/caac.21834 DOI: https://doi.org/10.3322/caac.21834
Santos MO, Lima FCS, Martins LFL, et al. Estimativa de incidência de câncer no Brasil, 2023-2025. Rev Bras Cancerol. 2023;69(1):e-213700. doi: https://doi.org/10.32635/2176-9745.RBC.2023v69n1.3700 DOI: https://doi.org/10.32635/2176-9745.RBC.2023v69n1.3700
SIM: Sistema de Informação sobre Mortalidade [Internet]. Versão 3.2.1.2. Brasília (DF): DATASUS. [data desconhecida] - [acesso 2025 jan 25]. Disponível em: http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sim/cnv/obt10br.def
Ministério da Saúde(BR). Portaria n° 958, de 26 de setembro de 2014. Aprova as Diretrizes Diagnósticas e Terapêuticas do Câncer de Cólon e Reto. Diário Oficial da União [Internet], Brasília, DF. 2014 set 29 [acesso 2025 jan 5]; Edição 187; Seção 1:59. Disponível em: https://pesquisa.in.gov.br/imprensa/jsp/visualiza/index.jsp?data=29/09/2014&jornal=1&pagina=59&totalArquivos=192
Benson AB, Venook AP, Adam M, et al. Colon cancer, version 3.2024. J Natl Compr Cancer Netw. 2024;22(2D):240029. doi: https://doi.org/10.6004/jnccn.2024.0029 DOI: https://doi.org/10.6004/jnccn.2024.0029
Benson AB, Venook AP, Adam M, et al. Rectal cancer, version 3.2024: featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw. 2024;22(6):366-75. doi: https://doi.org/10.6004/jnccn.2024.0041 DOI: https://doi.org/10.6004/jnccn.2024.0041
Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291-305. doi: https://doi.org/10.1016/j.annonc.2020.06.022 DOI: https://doi.org/10.1016/j.annonc.2020.06.022
Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10-32. doi: https://doi.org/10.1016/j.annonc.2022.10.003 DOI: https://doi.org/10.1016/j.annonc.2022.10.003
Afanasjeva J, Burk M, Cunningham F, et al. ASHP Guidelines on medication-use evaluation. Am J Heal Pharm. 2021;78(2):168-75. doi: https://doi.org/10.1093/ajhp/zxaa393 DOI: https://doi.org/10.1093/ajhp/zxaa393
Wettermark B, Elseviers M, Almarsdóttir AB, et al. Introduction to drug utilization research. In: Elseviers M, Wettermark B, Almarsdóttir AB, et al., organizadores. Drug utilization research. Wiley; 2016. p. 3-12. DOI: https://doi.org/10.1002/9781118949740.ch1
Organização Mundial da Saúde. CID-10: Classificação Estatística Internacional de Doenças com disquete. Vol. 3, Índice Alfabético. São Paulo: Edusp; 2008.
R: The R Project for Statistical Computing [Internet]. Version 4.4.3. [sem local]: The R foundation. [sem data] - [acesso 2017 jul 15]. Disponível em: https://www.R-project.org
Kleinbaum DG, Klein M. Kaplan-Meier survival curves and the log-rank test. In: Kleinbaum DG, Klein M, editors. Survival analysis. Statistics for biology and health. New York: Springer; 2012. p. 19-41. doi: https://doi.org/10.1007/978-1-4419-6646-9_2 DOI: https://doi.org/10.1007/978-1-4419-6646-9_2
Conselho Nacional de Saúde (BR). Resolução n° 466, de 12 de dezembro de 2012. Aprova as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. Diário Oficial da União, Brasília, DF. 2013 jun 13; Seção I:59.
Conselho Nacional de Saúde (BR). Resolução n° 510, de 7 de abril de 2016. Dispõe sobre as normas aplicáveis a pesquisas em Ciências Humanas e Sociais. Diário Oficial da União, Brasília, DF. 2016 maio 24; Seção I:44. DOI: https://doi.org/10.4322/0104-4931.ctoED2403
Rohenkohl CA, Pastorello J, Costa NR, et al. Epidemiological profile of patients with colorectal cancer from a hospital in Rio Grande do Sul, Brazil. J Coloproctology. 2021;41(1):001-7. doi: https://doi.org/10.1055/s-0041-1725048 DOI: https://doi.org/10.1055/s-0041-1725048
Mello MRSP, Moura SF, Muzi CD, et al. Clinical evaluation and pattern of symptoms in colorectal cancer patients. Arq Gastroenterol. 2020;57(2):131-6. doi: https://doi.org/10.1590/S0004-2803.202000000-24 DOI: https://doi.org/10.1590/s0004-2803.202000000-24
Carethers JM. Racial and ethnic disparities in colorectal cancer incidence and mortality. Adv Cancer Res. 2021;151:197-229. doi: https://doi.org/10.1016/bs.acr.2021.02.007 DOI: https://doi.org/10.1016/bs.acr.2021.02.007
Ministério da Saúde (BR). Rastreamento. Cadernos de atenção primária. Brasilia, DF: MS; 2010. v. 29.
Instituto Nacional de Câncer. Detecção precoce do câncer. Rio de Janeiro: INCA; 2021.
Toledo CM, Almeida LMPR, Averbach M, et al. Analysis of the tracking initiatives of colorectal cancer in Brazil. Arq Gastroenterol. 2023;60(4):450-62. doi: https://doi.org/10.1590/S0004-2803.230402023-93 DOI: https://doi.org/10.1590/s0004-2803.230402023-93
Kalidindi AV, Dubashi B, Jayanthi M, et al. Efficacy and safety of capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer. Indian J Cancer. 2022;59(1):73-9. doi: https://doi.org/10.4103/ijc.IJC_618_19 DOI: https://doi.org/10.4103/ijc.IJC_618_19
Tsuchiya A, Ogawa C, Kondo N, et al. Exploratory study on relative dose intensity and reasons for dose reduction of adjuvant CAPOX therapy in elderly patients with colorectal cancer. Glob Heal Med. 2022;4(3):2021.01018. doi: https://doi.org/10.35772/ghm.2021.01018 DOI: https://doi.org/10.35772/ghm.2021.01018
Neugut AI, Lin A, Raab GT, et al. FOLFOX and FOLFIRI use in stage IV colon cancer: analysis of SEER-medicare data. Clin Colorectal Cancer. 2019;18(2):133-40. doi: https://doi.org/10.1016/j.clcc.2019.01.005 DOI: https://doi.org/10.1016/j.clcc.2019.01.005
Melo MM, Cardoso RM, Silva MJS. Reação adversa a medicamento: uma análise comparativa de protocolos utilizados para o tratamento do câncer colorretal. Medicina (Ribeirão Preto). 2017;50(4);245-54. https://doi.org/10.11606/issn.2176-7262.v50i4p245-254 DOI: https://doi.org/10.11606/issn.2176-7262.v50i4p245-254
Yang W, Zheng H, Lv W, et al. Current status and prospect of immunotherapy for colorectal cancer. Int J Colorectal Dis. 2023;38(1):266. doi: https://doi.org/10.1007/s00384-023-04553-z DOI: https://doi.org/10.1007/s00384-023-04553-z
Adebayo AS, Agbaje K, Adesina SK, et al. Colorectal cancer: disease process, current treatment options, and future perspectives. Pharmaceutics. 2023;15(11):2620. doi: https://doi.org/10.3390/pharmaceutics15112620 DOI: https://doi.org/10.3390/pharmaceutics15112620
Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer. JAMA. 2017;317(23):2392. doi: https://doi.org/10.1001/jama.2017.7105 DOI: https://doi.org/10.1001/jama.2017.7105
Miyamoto Y, Hiyoshi Y, Sawayama H, et el. Precision medicine for adjuvant chemotherapy of resected colorectal cancer. Ann Gastroenterol Surg. 2020;4(6):635-45. doi: https://doi.org/10.1002/ags3.12397 DOI: https://doi.org/10.1002/ags3.12397
Yang L, Yang J, Kleppe A, et al. Personalizing adjuvant therapy for patients with colorectal cancer. Nat Rev Clin Oncol. 2024;21(1):67-79. doi: https://doi.org/10.1038/s41571-023-00834-2 DOI: https://doi.org/10.1038/s41571-023-00834-2
Zanatto RM, Santos G, Oliveira JC, et al. Impact of KRAS mutations in clinical features in colorectal cancer. ABCD Arq Bras Cir Dig (São Paulo). 2020;33(3):e1524. doi: https://doi.org/10.1590/0102-672020200003e1524 DOI: https://doi.org/10.1590/0102-672020200003e1524
Carvalho LEW, Sarraf JS, Oliveira ACM, et al. What is different in the population of the brazilian Amazon region so that they have a low frequency of KRAS gene mutations. Case Rep Oncol. 2017;10(2):777-82. doi: https://doi.org/10.1159/000479733 DOI: https://doi.org/10.1159/000479733
Tomasello G, Ghidini M, Galassi B, et al. Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis. Sci Rep. 2022;12(1):1055. doi: https://doi.org/10.1038/s41598-022-05065-6 DOI: https://doi.org/10.1038/s41598-022-05065-6
Published
How to Cite
Issue
Section
License
Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.
This work is licensed under a Creative Commons Attribution 4.0 International License.
